ArticleBlood transfusion = Trasfusione del sangue
Multicenter evaluation of soluble CD38: neutralizing anti-CD38 pan-reactivity to enable alloantibody detection.
Article in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Structural similarity between CD38 and the Duffy antigen as a potential mechanism of attenuated anti-Fy antibody reactivity with soluble CD38.British journal of haematology · 2026Article
- International multicentre evaluation of a new anti-idiotypic anti-daratumumab for resolving pre-transfusion interferences.Vox sanguinis · 2026Article
- Resolving the Interference of Anti-CD38 Antibodies on Blood Compatibility Assays Using CD38 "Baitbodies" Approach.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-CD38 is a monoclonal antibody treatment for multiple myeloma, B-cell malignancies, and autoimmune diseases that targets CD38 antigens on the cell surface. Red blood cells are CD38+, therefore anti-CD38 causes panagglutination, hindering immunohematology testing such as antibody screen, antibody identification, and crossmatch. This interference masks detection of clinically significant alloantibodies in pre-transfusion testing. MATERIALS AND
methodsTo assess the effectiveness of soluble CD38 (sCD38) in neutralizing anti-CD38 in the clinical setting and user satisfaction, plasma samples from patients receiving anti-CD38 therapy were collected between 0 and 150 days after the last infusion and tested according to routine laboratory procedures with an established sCD38 neutralization method (15 minutes incubation at 37°C with up to 6 μL of sCD38 per 25 μL of plasma). Neutralization was evaluated using antibody screening or crossmatching, by tube or gel card. Some samples were spiked with irregular antibodies to evaluate the impact of sCD38 on antibody detection. A survey assessed user satisfaction.
resultsIn total, 273 patient samples were evaluated (263 patients treated with daratumumab and 10 with isatuximab). sCD38 completely neutralized anti-CD38 present in 79.8% of samples tested using either 2 or 4 μL of sCD38. When either 2-4 or 6 μL of sCD38 was used, 98.5% of samples were neutralized. Except for anti-Fya and anti-Fyb, all spiked alloantibodies (anti-D, -c, -E, -K, -Jk DISCUSSION: sCD38 has demonstrated strong potential in neutralizing anti-CD38 drugs in the clinical setting. While tested against isatuximab and daratumumab, it could be a potentially universal solution. By mimicking CD38 antigen on red blood cells, sCD38 is likely to interact with a broad range of anti-CD38 antibodies, suggesting its possible applicability across various settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.